New breathing strategy could save lives in ARDS

NCT ID NCT07309783

First seen Jun 24, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This study tests whether a personalized ventilation strategy guided by electrical impedance tomography (EIT) can improve survival in adults with acute respiratory distress syndrome (ARDS). About 574 participants will be randomly assigned to receive either EIT-guided ventilation (including tailored prone positioning and PEEP settings) or standard protective ventilation. The main goal is to see if the EIT-guided approach lowers 28-day mortality.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Electrical impedance tomography (EIT)-guided ventilation strategy (including prone positioning and PEEP titration)
What this could lead to
If successful, this could provide a more effective way to ventilate ARDS patients, potentially reducing deaths and time on breathing machines.
What could go wrong
This is an early-stage trial (not yet recruiting) with 574 participants. The EIT-guided approach may not improve outcomes over standard care, and results may not apply to all ARDS patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.